

9 November 2021

Renal cell carcinoma and melanoma pharma

Q1 -3: Information as available from RISOH (Regional Information System Oncology Haematology) July – Sept 2021

Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma:

- Avelumab + Axitinib : 8
- Axinitib : 1
- Cabozantinib : 21
- Everolimus: 0
- Lenvantinib + Everolimus : 0
- Nivolumab : 34
- Nivolumab + Ipilimumab : 8
- Pazopanib : 1
- Pembrolizumab + Axitinib : 0
- Sunitinib : 10
- Temsirolimus : 0
- Tivozanib : 16
- Other : 0

Q2. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage):

- Cobimetinib : 0
- Dabrafenib : 2
- Dabrafenib AND Trametinib : 24
- Encorafenib AND Binimetinib : 20
- Ipilimumab : 0
- Ipilimumab AND Nivolumab : 14
- Nivolumab : 7
- Pembrolizumab : 47
- Trametinib : 0
- Vemurafenib : 0
- Vemurafenib AND Cobimetinib: 0
- Other active systemic anti-cancer therapy: 0
- Palliative care only : not available from RISOH

Q3. If possible, could you please provide the patients treated in the past 3 months with the following agents for metastatic melanoma ONLY: Manual check of Q2 Patients

- Cobimetinib : 0
- Dabrafenib : 2

9 November 2021

- Dabrafenib AND Trametinib: 8
- Encorafenib AND Binimetinib : 18
- Ipilimumab : 0
- Ipilimumab AND Nivolumab: 14
- Nivolumab : 5
- Pembrolizumab :20
- Trametinib : 0
- Vemurafenib : 0
- Vemurafenib AND Cobimetinib : 0
- Other active systemic anti-cancer therapy : 0
- Palliative care only :not available from RISOH

Q4. In the last 3 months, how many patients have undergone full or partial nephrectomy (any of the following OPCS codes M02.1, M02.2, M02.3, M02.4, M02.5, M03.1, M03.9, M04.2, M10.1 or M10.4)?

Response: Coding on our systems is only completed up to the end of July 2021.
The figure for the 3 months up to this date is: 141